NanoViricides Files Orphan Drug Application for NV-387 MPox Treatment Amid Current Therapy Failures
Key Insights
NanoViricides has filed an Orphan Drug Designation application with the US FDA for NV-387, targeting MPox (search) treatment in a market with no approved therapies.
Current MPox (search) treatments tecovirimat and brincidofovir have demonstrated clinical failures, with tecovirimat showing no effectiveness and brincidofovir causing liver toxicity in patients.
NV-387 has shown strong effectiveness in preclinical orthopoxvirus (search) models and completed Phase I trials with no adverse events, positioning it as a potential breakthrough therapy.
NanoViricides, Inc. has submitted an Orphan Drug Designation (ODD) application to the US FDA for NV-387, a novel antiviral treatment for Monkeypox (search) (MPox (search)), addressing a critical gap in effective therapeutics for this emerging viral threat. The Connecticut-based company's application comes as existing treatments continue to demonstrate significant clinical limitations.
Current Treatment Landscape Shows Critical Gaps
The MPox (search) treatment landscape reveals substantial unmet medical needs. Currently, no drugs are approved specifically for MPox treatment. Two existing therapies approved for smallpox (search) under the FDA's "Animal Rule" have shown concerning clinical performance.
Tecovirimat (TPOXX®, SIGA) failed to demonstrate clinical effectiveness in treating MPXV (search) infections, showing no viral load reduction benefit over standard of care in clinical trials. Additionally, mutants resistant to tecovirimat have been identified in some cases, raising concerns about long-term efficacy.
Brincidofovir (TEMBEXA®, EBS) has demonstrated even more serious safety concerns. In a peer-reviewed retrospective observational study, all three MPox (search) patients treated with brincidofovir developed drug-induced liver disease, requiring cessation of therapy. The treatment showed no effectiveness in these patients despite the severe adverse effects.
Viral Evolution Challenges Existing Approaches
The MPXV (search) continues to evolve in African regions, with mutants resistant to the JYNNEOS® Smallpox (search) vaccine emerging. Research indicates that antibody responses to MPXV from the JYNNEOS vaccine are poor and short-lived, further complicating prevention efforts.
According to peer-reviewed scientific articles, orthopoxviruses can escape both small chemical drugs, tecovirimat and brincidofovir, through mutations, highlighting the need for novel therapeutic approaches.
NV-387 Demonstrates Promising Preclinical Profile
NV-387 has shown strong effectiveness in a mouse model of dermal lethal infection with ectromelia, an orthopoxvirus (search) closely related to viruses causing smallpox (search) and MPox (search). The drug candidate has successfully completed a Phase I human clinical trial, demonstrating safety and tolerability in healthy adults with no reported adverse events.
The drug represents what the company describes as "an unusually broad-spectrum antiviral" that has demonstrated effectiveness in relevant animal models across multiple viral infections, including RSV (search), COVID (search), Influenza (search), MPox (search), Smallpox (search), and Measles.
Unique Mechanism Addresses Resistance Concerns
NV-387 operates as a complete chemical nanomachine that binds to, engulfs, and destroys virus particles without dependence on the human immune system. The drug mimics specific cell-side features that viruses continue to employ for effective infection of human host cells, potentially making viral resistance unlikely even as viruses mutate.
This mechanism contrasts with traditional vaccines, antibodies, and small chemical drugs, which can become ineffective as viral mutations occur.
Orphan Drug Strategy and Market Position
With approximately 2,042 MPox (search) cases reported in the USA in 2025, well below the 200,000-case threshold, NV-387 qualifies for Orphan Drug Designation. If granted, this designation would provide NanoViricides with incentives including tax credits, user fee exemptions, and potential market exclusivity.
The company employed Only Orphans Cote, LLC, founded by Dr. Timothy Cote, former Director of the US FDA Office of Orphan Products Development, to develop the ODD application. Dr. Cote's expertise in orphan drug regulations positions the application strategically.
Clinical Development Pipeline
NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials. The company's business model is based on licensing technology from TheraCour Pharma (search) Inc. for specific viral applications, with NV-387 serving as the lead drug candidate for multiple respiratory viral infections and poxvirus infections.
As Anil R. Diwan, PhD, emphasized, the evolving MPXV (search) virus represents a global threat that underscores the urgent need for effective therapeutics. The company's approach aims to address the limitations of current treatments while providing a platform for combating rapidly mutating viral threats.